Covestor Ltd Has $56,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Covestor Ltd boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 23.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 692 shares of the medical equipment provider’s stock after purchasing an additional 133 shares during the period. Covestor Ltd’s holdings in Hologic were worth $56,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Innealta Capital LLC acquired a new position in shares of Hologic in the second quarter valued at $25,000. Wolff Wiese Magana LLC bought a new position in Hologic in the third quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter worth $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the 2nd quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC increased its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Down 2.1 %

NASDAQ HOLX opened at $77.54 on Friday. The stock has a market capitalization of $18.01 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 2.52 and a beta of 0.98. The business’s fifty day moving average is $80.77 and its 200-day moving average is $78.22. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the company earned $0.89 earnings per share. Hologic’s revenue was up 4.5% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HOLX. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Royal Bank of Canada boosted their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.